Cell therapy advancements within oncology: the latest updates
Discover the latest breakthroughs in cancer regenerative therapies in this edition of RegMedNet’s Cell therapy weekly.
Featured developments include Dispatch Bio’s FDA clearance for DISP-10, an investigational therapy that utilizes their Flare platform to enhance immune recognition of cancer cells. The company has also forged a strategic partnership with CARsgen to initiate a DISP-11 trial within China. Additionally, Eureka Therapeutics secured FDA RMAT designation for ECT204, an autologous CAR-T therapy designed to tackle hepatocellular carcinoma through their ARTEMIS platform.